CD8A and acute myeloid leukemia: Large numbers of clonal CD8+ T cell expansions preceding the development of grade 2–3 irAEs and early diversification in peripheral TCRβ repertoire in patients who ultimately developed irAEs during treatment with ipilimumab have been reported.59 60 Our findings differ, as we did not observe broad repertoire shifts in terms of clonality or clonal T cell expansions until a minimum of 6 weeks after pembrolizumab initiation in our R-AML patients developing irAEs.